Baseline demographics and disease characteristics of patients randomized to the GALLIUM and GOYA trials
| Characteristic . | GALLIUM . | GOYA . |
|---|---|---|
| (n = 1202) . | (n = 1414) . | |
| Treatment: R/G | 601 (50.0)/601 (50.0) | 710 (50.2)/704 (49.8) |
| Median age, y (range) | 59 (23-88) | 62 (18-86) |
| Sex, male | 563 (46.8) | 750 (53.0) |
| Ann Arbor stage III/IV*† | 1092 (90.8) | 1073 (75.9) |
| Geographic region | ||
| Asia | 185 (15.4) | 514 (36.4) |
| Eastern Europe | 157 (13.1) | 196 (13.9) |
| Western Europe | 581 (48.3) | 426 (30.1) |
| North America | 152 (12.7) | 216 (15.3) |
| Other | 127 (10.6) | 62 (4.4) |
| Number of chemotherapy cycles | ||
| 6 | — | 1045 (73.9) |
| 8 | — | 369 (26.1) |
| Chemotherapy | ||
| Bendamustine | 686 (57.1) | — |
| CHOP | 399 (33.2) | — |
| CVP | 117 (9.7) | — |
| FLIPI score‡ | ||
| Low | 106 (9.1) | — |
| Intermediate | 584 (50.1) | — |
| High | 475 (40.8) | — |
| IPI category | ||
| Low | — | 282 (19.9) |
| Low-intermediate | — | 500 (35.4) |
| High-intermediate | — | 412 (29.1) |
| High | — | 220 (15.6) |
| COO§ | ||
| GCB | — | 540 (57.9) |
| ABC | — | 243 (26.1) |
| Unclassified | — | 150 (16.1) |
| BCL2 by IHC‖‖ | ||
| Negative | — | 392 (51.9) |
| Positive | — | 363 (48.1) |
| Characteristic . | GALLIUM . | GOYA . |
|---|---|---|
| (n = 1202) . | (n = 1414) . | |
| Treatment: R/G | 601 (50.0)/601 (50.0) | 710 (50.2)/704 (49.8) |
| Median age, y (range) | 59 (23-88) | 62 (18-86) |
| Sex, male | 563 (46.8) | 750 (53.0) |
| Ann Arbor stage III/IV*† | 1092 (90.8) | 1073 (75.9) |
| Geographic region | ||
| Asia | 185 (15.4) | 514 (36.4) |
| Eastern Europe | 157 (13.1) | 196 (13.9) |
| Western Europe | 581 (48.3) | 426 (30.1) |
| North America | 152 (12.7) | 216 (15.3) |
| Other | 127 (10.6) | 62 (4.4) |
| Number of chemotherapy cycles | ||
| 6 | — | 1045 (73.9) |
| 8 | — | 369 (26.1) |
| Chemotherapy | ||
| Bendamustine | 686 (57.1) | — |
| CHOP | 399 (33.2) | — |
| CVP | 117 (9.7) | — |
| FLIPI score‡ | ||
| Low | 106 (9.1) | — |
| Intermediate | 584 (50.1) | — |
| High | 475 (40.8) | — |
| IPI category | ||
| Low | — | 282 (19.9) |
| Low-intermediate | — | 500 (35.4) |
| High-intermediate | — | 412 (29.1) |
| High | — | 220 (15.6) |
| COO§ | ||
| GCB | — | 540 (57.9) |
| ABC | — | 243 (26.1) |
| Unclassified | — | 150 (16.1) |
| BCL2 by IHC‖‖ | ||
| Negative | — | 392 (51.9) |
| Positive | — | 363 (48.1) |
Data are number of patients (percentage of the total study group) unless otherwise specified.
ABC, activated B-cell; CVP, cyclophosphamide, vincristine, and prednisone; FLIPI, FL International Prognostic Index; G, obinutuzumab; GCB, germinal center B-cell; IHC, immunohistochemistry; IPI, International Prognostic Index; R, rituximab.
Data missing for 7 patients (GALLIUM).
Data missing for 1 patient (GOYA).
Data missing for 37 patients (GALLIUM).
Data missing for 481 patients (GOYA).
Data missing for 659 patients (GOYA).